- Home
- EDIT vs MAV Comparison
EDIT vs MAV Comparison
Compare EDIT & MAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- MAV
- Stock Information
- Founded
- EDIT 2013
- MAV 2003
- Country
- EDIT United States
- MAV United States
- Employees
- EDIT N/A
- MAV N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- MAV Finance Companies
- Sector
- EDIT Health Care
- MAV Finance
- Exchange
- EDIT Nasdaq
- MAV Nasdaq
- Market Cap
- EDIT 156.5M
- MAV 184.1M
- IPO Year
- EDIT 2016
- MAV N/A
- Fundamental
- Price
- EDIT $2.25
- MAV $8.23
- Analyst Decision
- EDIT Buy
- MAV
- Analyst Count
- EDIT 13
- MAV 0
- Target Price
- EDIT $6.73
- MAV N/A
- AVG Volume (30 Days)
- EDIT 2.4M
- MAV 66.2K
- Earning Date
- EDIT 08-06-2025
- MAV 01-01-0001
- Dividend Yield
- EDIT N/A
- MAV 4.30%
- EPS Growth
- EDIT N/A
- MAV N/A
- EPS
- EDIT N/A
- MAV N/A
- Revenue
- EDIT $35,837,000.00
- MAV N/A
- Revenue This Year
- EDIT N/A
- MAV N/A
- Revenue Next Year
- EDIT N/A
- MAV N/A
- P/E Ratio
- EDIT N/A
- MAV N/A
- Revenue Growth
- EDIT N/A
- MAV N/A
- 52 Week Low
- EDIT $0.91
- MAV $6.37
- 52 Week High
- EDIT $6.05
- MAV $8.34
- Technical
- Relative Strength Index (RSI)
- EDIT 63.76
- MAV 44.97
- Support Level
- EDIT $2.05
- MAV $8.25
- Resistance Level
- EDIT $2.55
- MAV $8.34
- Average True Range (ATR)
- EDIT 0.23
- MAV 0.06
- MACD
- EDIT 0.03
- MAV -0.01
- Stochastic Oscillator
- EDIT 66.29
- MAV 8.33
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About MAV Pioneer Municipal High Income Advantage Fund Inc.
Pioneer Muni High Income Advantage Tr is a closed-end fund designed to pursue high current income exempt from regular federal income tax and as a secondary objective to seek capital appreciation. It predominantly invests in debt securities and other obligations issued by or on behalf of states, territories, and possessions of the United States and the District of Columbia and their political subdivisions, agencies, and instrumentalities, the interest on which is exempt from regular federal income tax.